It was recently revealed by the firm Genzyme Corp, which is the Cambridge segment of the French firm Sanofi, that their drug Fabrazyme has been approved by the FDA for starting production again. The firm recently said that this new drug, which is meant for the cure of Fabry disease, has been approved for production by the Food and Drug Administration in the United States.

Yesterday, Sanofi-Aventis SA’s top executive, hours after squaring up an agreement of buying Genzyme Corp. for $20.1 billion plus potential additional payments, promised to protect the Genzyme brand, but he never guaranteed to keep all of the company’s four thousand five hundred Massachusetts jobs.

The French drug maker, Sanofi-Aventis SA, which made a hostile bid for Genzyme Corp., has extended the deadline to 21 January, for the U. S. shareholders of the biotechnology company to tender their stock.

Sanofi-Aventis, Pharma Giant on Sunday openly offered confirmation for the foremost time that it had bid for Genzyme Corp., earlier, and made a move to nudge investors of Genzyme to accept a proposal that the administration of Cambridge, Massachusetts, the firm up to now had snubbed.

Activist investor Carl Icahn is under plans to approach board of biotechnology company Genzyme Corp (GENZ. O) to consider taking CEO Henri Termeer off from his post as chairman of the board.

Genzyme Corp has been struggling through the roughest patch ever and informed on Monday that regulators have refused to approve its drug for the treatment of Pompe disease until the manufacturing deficiencies are addressed at its Allston Landing plant in Boston.
 

The Cambridge Biotechnology firm , Genzyme Corp had got approval to manufacture Myozyme in Europe and market it in the US.

According to a statement by Genzyme the European Commission has approved the 4,000-liter manufacturing process of Myozyme at its facility in Geel, Belgium.